These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 21288284

  • 1. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
    Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, Ochiya T, Kamiyama T, Umezawa K, Todo S.
    Cancer Sci; 2011 May; 102(5):1052-8. PubMed ID: 21288284
    [Abstract] [Full Text] [Related]

  • 2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.
    Clin Cancer Res; 2005 Feb 01; 11(3):1287-93. PubMed ID: 15709200
    [Abstract] [Full Text] [Related]

  • 3. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
    Sato M, Nakanishi K, Haga S, Fujiyoshi M, Baba M, Mino K, Yimin, Niwa H, Yokoo H, Umezawa K, Ohmiya Y, Kamiyama T, Todo S, Taketomi A, Ozaki M.
    Oncol Res; 2013 Feb 01; 21(6):333-43. PubMed ID: 25198663
    [Abstract] [Full Text] [Related]

  • 4. DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
    Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.
    Int J Oncol; 2006 Sep 01; 29(3):713-9. PubMed ID: 16865289
    [Abstract] [Full Text] [Related]

  • 5. Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
    Umezawa K.
    Biomed Pharmacother; 2011 Jul 01; 65(4):252-9. PubMed ID: 21723080
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
    Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M.
    Mol Pharmacol; 2009 Aug 01; 76(2):290-300. PubMed ID: 19461054
    [Abstract] [Full Text] [Related]

  • 7. Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
    Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.
    Arthritis Res Ther; 2005 Aug 01; 7(6):R1348-59. PubMed ID: 16277688
    [Abstract] [Full Text] [Related]

  • 8. Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
    Kuroda K, Horiguchi Y, Nakashima J, Kikuchi E, Kanao K, Miyajima A, Ohigashi T, Umezawa K, Murai M.
    Clin Cancer Res; 2005 Aug 01; 11(15):5590-4. PubMed ID: 16061877
    [Abstract] [Full Text] [Related]

  • 9. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
    Kawajiri H, Yashiro M, Shinto O, Nakamura K, Tendo M, Takemura S, Node M, Hamashima Y, Kajimoto T, Sawada T, Ohira M, Hirakawa K.
    Clin Cancer Res; 2008 May 01; 14(9):2850-60. PubMed ID: 18451253
    [Abstract] [Full Text] [Related]

  • 10. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, Yamashita S.
    Clin Cancer Res; 2004 Oct 15; 10(20):6821-9. PubMed ID: 15501958
    [Abstract] [Full Text] [Related]

  • 11. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T, Hoshino M, Aoki K, Ohya K, Komano Y, Nanki T, Miyasaka N, Umezawa K.
    Arthritis Res Ther; 2007 Oct 15; 9(5):R97. PubMed ID: 17892600
    [Abstract] [Full Text] [Related]

  • 12. Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
    Kodaira K, Kikuchi E, Kosugi M, Horiguchi Y, Matsumoto K, Kanai K, Suzuki E, Miyajima A, Nakagawa K, Tachibana M, Umezawa K, Oya M.
    Urology; 2010 Apr 15; 75(4):805-12. PubMed ID: 20156648
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
    Ueki S, Yamashita K, Aoyagi T, Haga S, Suzuki T, Itoh T, Taniguchi M, Shimamura T, Furukawa H, Ozaki M, Umezawa K, Todo S.
    Transplantation; 2006 Dec 27; 82(12):1720-7. PubMed ID: 17198266
    [Abstract] [Full Text] [Related]

  • 15. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
    Ohsugi T, Horie R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, Watanabe T, Umezawa K, Urano T.
    Carcinogenesis; 2005 Aug 27; 26(8):1382-8. PubMed ID: 15831528
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.
    J Bone Miner Res; 2005 Apr 27; 20(4):653-62. PubMed ID: 15765185
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
    Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K.
    Expert Rev Anticancer Ther; 2003 Dec 27; 3(6):793-8. PubMed ID: 14686701
    [Abstract] [Full Text] [Related]

  • 19. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
    Katsman A, Umezawa K, Bonavida B.
    Drug Resist Updat; 2007 Dec 27; 10(1-2):1-12. PubMed ID: 17306602
    [Abstract] [Full Text] [Related]

  • 20. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
    Poma P, Notarbartolo M, Labbozzetta M, Sanguedolce R, Alaimo A, Carina V, Maurici A, Cusimano A, Cervello M, D'Alessandro N.
    Int J Oncol; 2006 Apr 27; 28(4):923-30. PubMed ID: 16525642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.